UBS announced a net profit of $1.4 billion for the second quarter of 2019.Earningsread more
Japan and South Korea are part of a complex and tightly linked supply chain that produces electronic goods such as smartphones and laptops.Technologyread more
Michael Kugelman from the U.S.-based Wilson Center says other issues take precedence in the bilateral dialogue between the United States and Pakistan — namely, Afghanistan and...Asia Politicsread more
Beijing says it can still meet its 2019 growth target of between 6% and 6.5% and continues to roll out stimulus measures to prop up activity. China set a 2019 industrial...China Economyread more
A different oil pricing dynamic has been evolving with new supply calculations based on the U.S. as the world's largest producer.Market Insiderread more
The Massachusetts senator's alarm-sounding on consumer debt neglects to measure it against the growth in the economy and the ability to pay.Economyread more
Stocks in Asia Pacific edged up on Tuesday, as investors await closely-watched central bank meetings in the coming days.Asia Marketsread more
More than half of Venezuela's 23 states lost power on Monday, according to Reuters witnesses and reports on social media, a blackout the government blamed on an...World Politicsread more
Equifax will give consumers a range of options for monitoring their credit or making claims of fraud or data misuse, part of a $425 million restitution fund.Technologyread more
The deal between the White House and Democrats was earlier expected to raise the debt ceiling for two years and permanently end the sequester.Politicsread more
Britain's Antstream is jumping into the cloud gaming battle with a streaming platform for retro titles. And Tencent just backed the company.Technologyread more
Jim Cramer has always had the goal of alerting investors when an incredible opportunity reveals itself. He knows how to spot the stocks that keep heading higher without any end in sight.
For instance, the $2.3 billion drug developer Esperion Therapeutics has been on a tear lately as investors anticipate its pill that is designed to lower levels of bad cholesterol in patients who are unable to take traditional statins.
The stock more than tripled last year, and then on Tuesday the company announced promising phase 2 data for its anti-cholesterol pill that sent it to $99 from $77.
"At that point you might have thought that the run was finished, especially since Esperion announced a 1.75 million share secondary offering on Tuesday night. But you would have been wrong," the "Mad Money" host said.
The secondary deal offered $100 per share, and considering that it closed at $110 on Thursday investors could have made a killing already.
Could this stock head even higher in 2015? To find out, Cramer spoke with Esperion CEO Tim Mayleben.
"I don't know the explanation for the stock activity for sure, but we are very excited about the drug that we are developing. It's got a particularly unsexy name…but we think it's one of the most attractive drugs in development," Mayleben said.
In recent studies, the new drug was able to lower LDL cholesterol by itself and also in combination with the traditional treatment of statins.
"That's vitally important for patients who are taking a medicine like this or could take a medicine like this for the rest of their lives," the CEO added.
Read more from Mad Money with Jim Cramer
Cramer Remix: Oil news you've waited on
Starbucks CEO speaks out on race
Cramer: $$ rolling into this sector—thanks to Fed
Mayleben explained that while Regeneron, Sanofi and Amgen all have cholesterol therapies up for approval with the FDA this year, what separates Esperion from the pack is that this is a once-a-day pill that does not require injection.
"We hold the radical belief that patients will prefer an oral once-daily pill, rather than have to self-inject or go to their doctor for an injection," he said.